These authors contributed equally to this work.
Article first published online: 8 MAY 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 57, Issue 6, pages 2124–2134, June 2013
How to Cite
Grebely, J., Feld, J. J., Applegate, T., Matthews, G. V., Hellard, M., Sherker, A., Petoumenos, K., Zang, G., Shaw, I., Yeung, B., George, J., Teutsch, S., Kaldor, J. M., Cherepanov, V., Bruneau, J., Shoukry, N. H., Lloyd, A. R. and Dore, G. J. (2013), Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 57: 2124–2134. doi: 10.1002/hep.26263
Potential conflict of interest: J.G. is a consultant/advisor for Merck. G.D. is a consultant/advisor and has received research grants from Roche, Merck, Janssen, Gilead, Bristol Myers Squibb.
Funded by the National Institutes of Health grant RO1 DA 15999-01. The Kirby Institute for Infection and Immunity in Society is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The HEPCO Cohort is supported by grants from the Canadian Institutes for Health Research (CIHR) (MOP-106468 and HEO-115696) and Fonds de recherche du Québec – Santé (FRQS) AIDS and Infectious Disease Network (Réseau SIDA-MI). Roche Pharmaceuticals supplied financial support for pegylated IFN-alfa-2a/ribavirin. J.G. is supported by a National Health and Medical Research Council Career Development Fellowship. G.D. and A.L. were supported by National Health and Medical Research Council Practitioner Research Fellowships. M.H. and J.K. were supported by National Health and Medical Research Council Research Fellowships. N.H.S. and J.B. hold Chercheur Boursier salary awards from the FRQS. The Burnet Institute receives funding support from the Victorian Operational Infrastructure Support Program, Department of Health, Victoria, Australia.
- Issue published online: 12 JUN 2013
- Article first published online: 8 MAY 2013
- Accepted manuscript online: 16 JAN 2013 10:57AM EST
- Manuscript Accepted: 19 DEC 2012
- Manuscript Received: 21 OCT 2012
Additional Supporting Information may be found in the online version of this article.
|HEP_26263_sm_SuppFig1.tif||1133K||Supporting Figure 1. Correlation between plasma IP-10 and HCV RNA at time of acute HCV detection among HCV RNA positive participants with available IP-10 levels and quantitative HCV RNA at time of acute HCV detection and CC rs12979860 genotype (n=78) and CT/TT rs12979860 genotypes (n=82).|
|HEP_26263_sm_SuppFig2.tif||1441K||Supporting Figure 2. Longitudinal measurement of HCV RNA, plasma IP-10 and ALT levels among individuals with A) Spontaneous HCV clearance; B) Persistent HCV infection.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.